Zhejiang Ausun Pharmaceutical Co (603229) Fair Value & Analysis
Healthcare · CN · Market cap 7.0B CNY
Fair value as of: Jul 11, 2026
From 26 valuation models · updated 30 days ago
Fair value updated Jul 11, 2026, revised from ¥3.46 to ¥5.78 (+67.1%) since Jun 24, 2026. Share price +1.6% over the past month.
Below-average quality, and screening another 28% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥7.22). The favourable scenario is already priced in.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range ¥6.01 – ¥31.11 · fair‑value band ¥4.33 – ¥7.22 · the ¥8.08 price screens above the ¥5.78 fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Zhejiang Ausun Pharmaceutical Co (603229) currently trades at ¥8.08, while our model-based Fair Value estimate is ¥5.78, implying the stock looks roughly 28.5% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhejiang Ausun Pharmaceutical Co generated revenue of 795M CNY at a net margin of 13.6%. Revenue grew 0.7% year over year. It earns a return on equity of 4.6%. The balance sheet holds a net cash position of 825M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥4.33 (bear case) to ¥7.22 (bull case); at ¥8.08, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -28%, 603229 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥4.16) versus Dividend Discount (¥1.65). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products.
Full company description
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is based in Linhai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Ausun Pharmaceutical Co reported revenue of ¥793M in FY2025 versus ¥570M in FY2021, a compound +8.6%/yr. Reported net income was ¥131M in FY2025, compounding −2.7%/yr from FY2021.
603229 screens 28% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Zhejiang Ausun Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang Ausun Pharmaceutical Co (603229) overvalued or undervalued?
What is the fair value of 603229?
What is the quality score of 603229?
What is the revenue of Zhejiang Ausun Pharmaceutical Co (603229)?
What is the net profit margin of 603229?
Does Zhejiang Ausun Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Ausun Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.